Interim report
Page 1
orexo Q3 2021 Interim Report Steady progression on our journey to build a broader and stronger Orexo Q3 2021 highlights > Total net revenues of SEK 145.9 m ( 150.3 ) > Net earnings of -52.0 SEK m ( -84.9 ) > EBITDA of SEK -47.4 m ( -20.9 ) > US Pharma segment ( ZUBSOLVⓇ US ) net revenues of SEK 136.4 m ( 143.8 ) , in local currency USD 15.8 m ( 16.2 ) , US Pharma EBIT of SEK 78.5 m ( 72.4 ) > Cash flow from operating activities of SEK -79.7 m ( -12.9 ) , cash balance of SEK 588.1 m ( 593.3 ) > Earnings per share before dilution amounted to -1.51 ( -2.45 ) > Commercial partnership agreement signed with Sober Grid , the largest global social media network for people in addiction recovery , giving a large group of users access to VORVIDAⓇ and DEPREXISⓇ > Lead pharmaceutical pipeline asset , OX124 - a rescue medication for overdoses , entered pivotal trial > Commercial agreement for VORVIDAⓇ and DEPREXISⓇ signed with Benefis Health System , a leading regional health network Important events after the period > MODIA ™ paper published in the Journal of Medical Internet Research Mental Health > Updated financial outlook , FY 2021 SEK 78 m US Pharma EBIT 58 % SEK 588 m US Pharma EBIT margin Cash and cash equivalents SEK m , unless otherwise stated 2021 Jul - Sep 2020 Jul - Sep 2021 Jan - Sep 2020 Jan - Sep 2020 Jan - Dec Net revenues Cost of goods sold 145.9 150.3 421.0 504.4 663.6 -21.3 -14.5 -58.6 -54.3 -65.6 Operating expenses -183.7 -165.4 -512.4 -459.0 -617.9 EBIT -59.0 -29.6 -150.0 -8.9 -19.9 EBIT margin , % -40.5 -19.7 -35.6 -1.8 -3.0 EBITDA -47.4 -20.9 -112.6 17.9 19.0 Earnings per share , before dilution , SEK -1.51 -2.45 -4.59 -1.00 -2.45 Earnings per share , after dilution , SEK -1.51 -2.45 -4.59 -1.00 -2.45 Cash flow from operating activities -79.7 -12.9 -148.4 28.0 16.8 Cash and cash equivalents 588.1 593.3 588.1 593.3 505.3 Unless otherwise stated in this report , all data refers to the Group , and numbers relate to the current quarter while numbers in parentheses relate to the corresponding period in 2020 . OREXO INTERIM REPORT Q3 2021 1